DrugPatentWatch Database Preview

Details for Patent: RE41911

« Back to Dashboard

Which drugs does patent RE41911 protect, and when does it expire?

Patent RE41911 protects IXEMPRA KIT and is included in one NDA.

Protection for IXEMPRA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-eight patent family members in thirty-seven countries.

Summary for Patent: RE41911

Title:	Epothilone derivatives
Abstract:	The present invention relates to epothilone derivatives, having the following formula ##STR00001## in which the variables G, W, Q, X, Y, B.sub.1, B.sub.2, Z.sub.1, Z.sub.2, and R.sub.1-R.sub.7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
Inventor(s):	Vite; Gregory D. (Titusville, NJ), Kim; Soong-Hoon (Lawrenceville, NJ), Borzilleri; Robert M. (Lawrenceville, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	12/539,492
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent RE41911

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007		RX	Yes	Yes					Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-002	Oct 16, 2007		RX	Yes	Yes					Y

International Family Members for US Patent RE41911

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	013358
Austria	309236
Austria	426598
Australia	731497
Australia	7972098